Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Cash from Financing Activities (2019 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Cash from Financing Activities for 13 consecutive years, with $9.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Financing Activities fell 54.7% to $9.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $256.0 million, a 65.18% decrease, with the full-year FY2025 number at $256.0 million, down 65.18% from a year prior.
  • Cash from Financing Activities was $9.0 million for Q4 2025 at Madrigal Pharmaceuticals, down from $236.6 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $573.7 million in Q1 2024 to a low of $1.7 million in Q2 2025.
  • A 5-year average of $115.0 million and a median of $46.0 million in 2022 define the central range for Cash from Financing Activities.
  • Peak YoY movement for Cash from Financing Activities: surged 5928.29% in 2021, then plummeted 98.7% in 2025.
  • Madrigal Pharmaceuticals' Cash from Financing Activities stood at $19.5 million in 2021, then skyrocketed by 1255.37% to $264.3 million in 2022, then skyrocketed by 81.55% to $479.9 million in 2023, then plummeted by 95.88% to $19.8 million in 2024, then plummeted by 54.7% to $9.0 million in 2025.
  • Per Business Quant, the three most recent readings for MDGL's Cash from Financing Activities are $9.0 million (Q4 2025), $236.6 million (Q3 2025), and $1.7 million (Q2 2025).